Retrospective analysis of patients with Graves orbitopathy treated by pulses of methylprednisolone, with focus on adverse events

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F18%3AN0000053" target="_blank" >RIV/00098892:_____/18:N0000053 - isvavai.cz</a>

Alternative codes found

RIV/61989592:15110/18:73589413

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Retrospective analysis of patients with Graves orbitopathy treated by pulses of methylprednisolone, with focus on adverse events

Original language description

Objective: Graves orbitopathy (GO) is an extrathyroidal manifestation of autoimmune thyroid disease. Early treatment with glucocorticoids in appropriately selected patients is recommended for active, moderate to severe, and sight-threatening disease. The recently published European Group on Graves Orbitopathy guidelines re-evaluated the recommended doses of intravenous methylprednisolone (ivMP) in response to the potential for adverse effects. We retrospectively reviewed our patient cohort treated with our ivMP protocol and analyzed the side effects of this treatment when given during hospitalization in our tertiary referral center. Methods: Between May 2007 and May 2017, a total of 171 consecutive patients with active, moderate to severe, or sight-threatening GO were treated with ivMP in a cumulative dose of 7.5 grams, given monthly in three hospital sessions. Adverse events were reported using Version 4 of Common Terminology Criteria for Adverse Events. Results: Ninety-two percent of patients who started the treatment were able to finish it; 5 % did not finish the study due to adverse events, and 3 % did not finish the treatment protocol because of noncompliance. The most common adverse events were asymptomatic changes in laboratory values (liver enzymes), psychiatric disorders, and infectious complications. None of the patients in the study died during the ivMP treatment, including those patients who experienced adverse effects or discontinued the protocol because of noncompliance. Conclusion: High-dose ivMP for active, moderate to severe, and sight-threatening GO, when applied cautiously in carefully selected and monitored patients, is generally safe during the treatment period.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30202 - Endocrinology and metabolism (including diabetes, hormones)

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Endocrine Practice

ISSN

1530-891X

e-ISSN

—

Volume of the periodical

24

Issue of the periodical within the volume

7

Country of publishing house

US - UNITED STATES

Number of pages

6

Pages from-to

652-657

UT code for WoS article

000439886600006

EID of the result in the Scopus database

2-s2.0-85050679296